

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/628,387
Filing Date 08/01/2000
First Named Inventor Soon-Shiong
Group Art Unit 1615
Examiner Name A. Pulliam
Attorney Docket Number AB1150-18 (0712400218)

RECEIVED
MAR 13 2002
TECH CENTER 1600-200

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
AUP	1	6,096,331		Desai et al.	08/01/00	
	2	5,916,596		Desai et al.	06/29/99	
	3	5,665,382		Grinstaff et al.	09/09/97	
	4	5,498,421		Grinstaff et al.	03/12/96	
	5	5,439,686		Desai et al.	08/08/95	
	6	5,362,478		Desai et al.	11/08/94	
	7	5,560,933		Soon-Shiong et al.	10/01/96	
	8	5,641,803		Carretta et al.	06/24/97	
	9	5,001,235		Kim	03/19/91	
	10	5,006,650		Barbachyn	04/09/91	
	11	5,015,737		Kim	05/14/91	
	12	5,416,071		Igari et al.	05/16/95	
	13	5,432,166		Peck et al.	07/11/95	
	14	5,434,143		Spielvogel et al.	07/18/95	
	15	5,442,062		Koh et al.	08/15/95	
	16	5,457,119		Bonjouklian et al.	10/10/95	
	17	5,464,841		Portoghese et al.	11/07/95	
	18	5,464,865		Demers et al.	11/07/95	
	19	5,468,480		Barrett et al.	11/21/95	
	20	5,468,741		Yen	11/21/95	
	21	5,616,320		Argoudelis et al.	04/01/97	
	22	6,020,368		Hinks et al.	02/02/00	
	23	6,218,377	B1	Stogniew et al.	04/17/01	
	24	6,218,426	B1	Anderson et al.	04/17/01	
	25	6,225,311	B1	Levin et al.	05/01/01	
	26	6,225,342	B1	Habtemariam et al.	05/01/01	
	27	6,228,985	B1	Blood et al.	05/08/01	
	28	6,239,175	B1	Hinks et al.	05/29/01	

BEST AVAILABLE COPY

Examiner Signature


Amke R

Date Considered

5/14/02

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



RECEIVED
MAR 18 2002
TECHNICAL CENTER 1600/2002

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/628,387
Filing Date	08/01/2000
First Named Inventor	Soon-Shiong
Group Art Unit	1615
Examiner Name	A. Pulliam
Attorney Docket Number	ABI1150-18 (071243-0018)

Sheet 1 of 3

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No++
ALP	1	O'Connell et al., <i>Phase I Trial of Taxol Given As a Three Hour Infusion Every Three Weeks</i> , 26 Proceedings of the AACR, 169 (Abstract 671) (1985)		
	2	Longnecker et al., <i>Phase I and Pharmacokinetic Study of Taxol in Patients with Advanced Cancer</i> , 4 Proceedings of ASCO, 32 (C-119) (1985)		
	3	Donehower et al., <i>Phase I Trial of Taxol in Patients with Advanced Cancer</i> , 71 Cancer Treatment Reports, Vol. 71, No. 12, 1171-77 (Dec. 1987)		
	4	Waugh et al., <i>Stability, compatability and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers</i> , Am. J. Hosp. Pharm. Vol. 48, No. 7, 1520-24 (July, 1991)		
	5	Kris et al., <i>Phase I Of Taxol Given As A 3-Hour Infusion Every 21 Days</i> , 70 Cancer Treatment Reports, 605-607 (1986)		
	6	Rowinsky et al., <i>Phase II Study of Taxol in Advanced Ovarian Epithelial Malignancies</i> , 7 Proceedings of ASCO (523) (1988)		
	7	McGuire et al., <i>Taxol: A Unique Antineoplastic Agent With Significant Activity In Advanced Ovarian Epithelial Neoplasms</i> , 111 Annals of Internal Medicine 273-279 (1989)		
	8	Thigpen et al., <i>Phase II Trial of Taxol as Second-Line Therapy for Ovarian Carcinoma: A Gynecologic Oncology Group Study</i> , 9 Proceedings of ASCO (604) (1990)		
	9	Rowinsky, <i>Taxol: A Novel Investigational Antimicrotubule Agent</i> , 82 J. Nat. Canc. Inst. 1247-1258 (1990)		
	10	The American Heritage Dictionary of the English Language 553, 1987 (3d ed. 1992)		
	11	Remington's Pharmaceutical Sciences 1752-54 (18th ed. 1990)		
	12	Physicians' Desk Reference 682-85 (49th ed. 1995)		
	13	Eisenhauer et al., <i>European-Canadian Randomized Trial of Paclitaxel in Relapsed Ovarian Cancer: High-Dose Versus Low-Dose and Long Versus Short Infusion</i> , J. Clin. Oncology, 2654-66 (Dec. 1994)		
	14	The United States Pharmacopeia 24 (Jan. 1, 2000), pp. 1-14 (<i>General Notices And Requirements</i>); 1775-1777 (<1> <i>Injections</i>); 1930-1936 (<661> <i>Containers</i>); 2107-2228 (<1151> <i>Pharmaceutical Dosage Forms</i>); 2143-2148 (<1211> <i>Sterilization And Sterility Assurance Of Compendial Articles</i>).		
	15	Physicians' Desk Reference, 55th.ed. (2001), pp. 1059-1067		
	16	Dispensing of Medication (John E. Hoover ed., 8th ed. 1976), pp. 1-16 (ch. 1), 255-295 (ch. 10)		
	17	The Practice of Pharmacy, pp. 404-427, (Donald C. McLeod & William A. Miller eds., 1st ed. 1981)		
	18	Remington: The Science and Practice of Pharmacy (20th ed.), pp. 780-806 (ch. 41), 807-820 (ch. 42), 1911-1931 (ch. 111)		
	19	Handbook of Institutional Pharmacy Practice (Mickey C. Smith & Thomas R. Brown eds., 1979) pp. 52-61, 257-289, 302-324, 620-634		


RECEIVED

MAR 1 3 2002

TECH CENTER 1600/2900

20	Practice Standards of ASHP 1996-1997, American Society of Health-System Pharmacists, Practice Standards of ASHP pp. 11, 18-20, 30-38, 96-102, 118-119, 130-146, 165-175, 293-296		
21	Fundamentals of Nursing (LuVerne Wolff et al. eds., 6th ed.), pp. 597-644		
22	Packaging Drugs and Pharmaceuticals (Wilmer A. Jenkins & Kenton R. Osborn eds.), pp. 1-9, 32-37, 54-65, 309-326, 332, 343		
23	Bryony S. Dean et al., Comparison of medication errors in an American and a British Hospital, <i>Am. J. Health-Syst. Pharm.</i> 52, 2543-9 (1995)		
24	Harald O. Schwarz, Bret A. Brodowy, Implementation and Evaluation of an Automated Dispensing System, <i>Am. J. Health-Syst. Pharm.</i> 52, 823-828 (1995)		
25	John P. Santell, ASHP National Survey of Hospital-Based Pharmaceutical Services – 1994, <i>Am. J. Health-Syst. Pharm.</i> 52, 1179-1198 (1995)		
26	Fred Puckett, Medication-Management Component of a Point-of-Care Information System, <i>Am. J. Health-Syst. Pharm.</i> 52, 1305-1309 (1995)		
27	Neil J. Facchinetti et al., Evaluating Error Detection Rates in a Hospital Pharmacy, <i>Med. Care</i> 37, 39-43 (1999)		
28	Joseph Perricone, William Hughes, Cost effective method of implementing decentralized unit dose pharmacy services in a Friesen setting, <i>Hospital Pharmacy</i> 19, 817-822 (1984)		
29	Katja Taxis et al., Hospital drug distribution systems in the UK and Germany – a study of medication errors, <i>Pharmacy World & Science</i> 21, 25-31 (1999)		
30	Compliance Policy Guides Manual, Human Drugs, Chapter 4, § 430.100 United Dose Labeling for Solid and Liquid Oral Dosage Forms (CPG 7132b.10) available at http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg430-100.html		
31	<i>Dictionary of Pharmacy</i> 74 (University of South Carolina Press) (1986)		
32	12 <i>Encyclopedia of Pharmaceutical Technology</i> (James Swarbrick & James C. Boylan eds., 1995)		
33	William E. Hassan, Jr., <i>Hospital Pharmacy</i> 278-94 (5th ed. 1986)		
34	<i>Human Drugs</i> , Compliance Policy Guides Manual ch. 4, § 480.200, at http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg480-200.html (August 2001)		
35	<i>Guidelines for Unit Dose Dispensing</i> , Arizona Board of Pharmacy Substantive Policies, available at http://www.pharmacy.state.az.us/link69.htm		
36	Healthcare Compliance Packaging Council, available at http://www.unitdose.org/ (<i>Glossary of Pharmaceutical Packaging Terms</i> , Healthcare Compliance Packaging Council, available at http://www.unitdose.org/glossary.htm)		
37	Clarence W. Taber, <i>Taber's Cyclopedic Medical Dictionary</i> 1941 (16th ed. 1989)		
38	Thomas J. Garrison, <i>Medication Distribution Systems</i> , Handbook of Institutional Pharmacy Practice ch. IV.1, 259 (Mickey C. Smith & Thomas R. Brown eds., 1979)		
39	Ken Harms & F. Maurice Smith, <i>Packaging Pharmaceuticals in Institutions</i> , Handbook of Institutional Pharmacy Practice ch. IV.6, 302 (Mickey C. Smith & Thomas R. Brown eds., 1979)		
40	Clyde Buchanan, <i>Unit Dose Drug Distribution</i> , The Practice of Pharmacy ch. 33, 404 (Donald C. McLeod & William A. Miller eds.) (1st ed. 1981)		
41	<i>ASHP Technical Assistance Bulletin on Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages</i> , Practice Standards of American Society of Health-System Pharmacists 118-19 (1996-1997)		
42	<i>ASHP Statement on Unit Dose Drug Distribution</i> , Practice Standards of American Society of Health-System Pharmacists 11 (1996-1997)		
43	Marc R. Summerfield, <i>Unit Dose Primer</i> 9-10 (1983)		
44	James C. Boylan et al., <i>Parenteral Products</i> , Modern Pharmaceutics, ch. 12, 441-87 (Gilbert S. Banker & Christopher T. Rhodes eds.) (3rd ed. 1996)		

45	Best Practices for Health-System Pharmacy, American Society of Health-System Pharmacists (2000-2001 ed.), pp. 42-57, 85, 87-97		
46	The Pink Sheet 55(1): 8-9 (January 4, 1993)		

Examiner Signature		Date Considered	5/14/02
--------------------	---	-----------------	---------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).